Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in four abstracts on investigational protein therapeutics sotatercept and luspatercept will be presented by Acceleron, its collaboration partner Celgene and clinical investigators at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held in San Francisco, California on December 6-9, 2014.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
